Limited Submission Funding Opportunities – updated 9/30/22

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. George M. O’Brien Kidney National Resource Centers (U54 – Clinical Trial Not Allowed)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for the George M. O’Brien Kidney Consortium – National Resource Centers (NRCs) to lead a nation-wide effort to advance kidney research. By establishing this Consortium, the NIDDK aims to expand the breadth and impact of this program and achieve following outcomes: (1) improved coordination among Centers, (2) enhancement of national outreach and sharing, and (3) promote continuous technological innovations. The Consortium will consist of ~8 National Resource Centers (NRCs) and one National Coordinating Center (NCC). The NRCs will; (1) establish theme-based cores to develop and nationally share unique resources, tools, technologies, services, and expertise that will support and advance kidney research, (2) promote the development of novel resources to stay abreast of emerging trends, (3) Promote inclusion of investigators from diverse scientific disciplines, (4) Promote the inclusion of investigators and fellows
Limited Submission Funding Opportunities – updated 9/30/22

from diverse backgrounds, and (5) expand the pool of investigators pursuing kidney research by attracting investigators that are new or from non-renal fields to join the kidney research community.

MGH LOI Deadline: 9/30/22
NIH LOI Deadline: 11/01/22
NIH Application Deadline: 12/01/22

Learn more

2. National Coordinating Center for the George M. O’Brien Kidney National Resource Centers (U24 – Clinical Trial Not Allowed)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for the George M. O’Brien Kidney Consortium -- National Coordination Center (NCC) to lead a nation-wide effort to advance kidney research. The O’Brien Kidney Consortium will consist of ~8 National Resource Centers (NRCs) tasked with developing and sharing specialized kidney resources tools, technologies, services, and expertise and one NCC to lead, manage, and harmonize all aspects of the Consortium. Specifically, the NCC will: (1) provide administrative support and coordination for the entire Consortium, (2) establish and curate a “one-stop-shop” sharing portal for the entire Consortium, (3) develop and implement a multipronged communication and education plan for researchers and students interested in conducting kidney research to maximize national outreach and impact, (4) ensure that patient viewpoints, priorities, and preferences inform all aspects of the Consortium, and (5) administer and manage a national Opportunity Pool program to address gaps and promote collaboration.

MGH LOI Deadline: 9/30/22
NIH LOI Deadline: 11/01/22
NIH Application Deadline: 12/01/22

Learn more

3. Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2023 (R24 Clinical Trial Not Allowed)
The purpose of this funding announcement is to support a coordinating center for the NICHD Population Dynamics Centers Research Infrastructure Program (PDRIP). The PDRIP is comprised of recipients that have active support from RFA-HD-18-013, RFA-HD-19-014, RFA-HD-20-015, RFA-HD-21-010, RFA-HD-22-013, and predecessor and successor announcements.

MGH LOI Deadline: 10/03/22
NIH LOI Deadline: 11/02/22
NIH Application Deadline: 12/02/22

Learn more
4. Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT – CCC) (U01 Clinical Trial Not Allowed) – NEW!
The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Clinical Coordinating Center (CCC) in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials, phase 2-3 trials if warranted by the nature of the studied population (such as rare diseases), and platform trials where applicable. In addition, the CCC will organize and maintain a gene therapy consortium, for the purposes of conduction early phase gene therapy trials in rare diseases.

The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations.

While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities.

This FOA solicits applications for the Clinical Coordinating Center (CCC). Separate FOAs solicit applications for the Clinical Sites and the Data Coordinating Center.

MGH LOI Deadline: 10/10/22
NIH LOI Deadline: 10/21/22
NIH Application Deadline: 11/21/22

Learn more

5. Data Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT – DCC) (U01 Clinical Trial Not Allowed) – NEW!
The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Data Coordinating Center (DCC) in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials, phase 2-3 trials if warranted by the nature of the studied population (such as rare diseases), and platform trials where applicable. In addition, the DCC will offer data coordination and statistical support to the Gene Therapy Consortium organized by the CCC.

The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations.

While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities.

This FOA solicits applications for the DCC. Separate FOAs solicit applications for the Clinical Sites and the Clinical Coordinating Center.
6. **Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed) – NEW!**

The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials, phase 2-3 trials if warranted by the nature of the studied population (such as rare diseases), and platform trials where applicable. In addition, the network will conduct early phase gene therapy trials through a gene therapy consortium organized by the CCC.

The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations.

While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities.

This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center.

**Learn more**

7. **Pediatric Clinical Pharmacology Research Career Development Award (K12 Clinical Trial Not Allowed)**

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that support mentored research and career development experiences for scholars pursuing clinical, translational, and/or basic research in pediatric therapeutics. This program constitutes a national network of mentors and scholars, in contrast to K12 programs that are based solely at a single applicant institution. The primary purpose of this FOA is to ensure that a pipeline of diverse and highly trained workforce is available in pediatric pharmacology-related clinical and biomedical fields that currently have a limited number of researchers. This FOA will support essential research career development opportunities and ensure “protected” time to pursue impactful research experiences for new faculty-level clinical pharmacologists, fostering the transition to productive highly skilled clinical pharmacologist investigators.

**Learn more**
Limited Submission Funding Opportunities – updated 9/30/22

This initiative proposes to expand and strengthen the community of clinical pharmacologist investigators engaged in pediatric clinical pharmacology research.

**MGH LOI Deadline: 10/19/22**
NIH Application Deadline: 12/06/22

Learn more

8. **Postbaccalaureate Research Education Program (PREP) (R25 – Independent Clinical Trial Not Allowed)**

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- **Courses for Skills Development**
- **Research Experiences**

This Funding Opportunity Announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research education programs will incorporate extensive research experiences and well-designed courses for skills development to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous, research-focused biomedical doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.). This program is limited to applications from doctoral degree-granting institutions that are research-intensive (i.e., those with NIH research project grant (RPG) funding averaging greater than or equal to $7.5 million in total costs per year over the last three fiscal years).

This FOA does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

**MGH LOI Deadline: 11/08/22**
NIH Application Deadline: 1/31/23

Learn more

9. **NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)**

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to
Limited Submission Funding Opportunities – updated 9/30/22

help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply.

*This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOAs (RFA-CA-22-036 or RFA-CA-22-037).*

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs (RFA-CA-22-035, RFA-CA-22-036, and/or RFA-CA-22-037). In your letter of intent, please indicate which are you are submitting under: **Data Science, Cancer Control Science, or Other Sciences.**

**MGH LOI Deadline: 12/15/22**
NIH Application Deadline: 2/28/23

[Learn more](#)

**10. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)**

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-22-035).

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs (RFA-CA-22-035, RFA-CA-22-036, and/or RFA-CA-22-037). In your letter of intent, please indicate which are you are submitting under: **Data Science, Cancer Control Science, or Other Sciences.**

**MGH LOI Deadline: 12/15/22**
NIH Application Deadline: 2/28/23

[Learn more](#)
11. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers
(K99/R00 – Independent Basic Experimental Studies with Humans Required)

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-22-035).

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs (RFA-CA-22-035, RFA-CA-22-036, and/or RFA-CA-22-037). In your letter of intent, please indicate which are you are submitting under: Data Science, Cancer Control Science, or Other Sciences.

MGH LOI Deadline: 12/15/22
NIH Application Deadline: 2/28/23

Learn more